JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB99819

Anti-Human IgG4 pFc’ [HP6023] (PE)

Be the first to review this product! Submit a review

|

(1 Publication)

Suitable for Dot, ELISA, WB, IHC-Fr, ICC/IF. Cited in 1 publication.

View Alternative Names

Immunoglobulin heavy constant gamma 4, Ig gamma-4 chain C region, IGHG4

  • Unconjugated

    Anti-Human IgG4 pFc’ [HP6023]

  • 519 FITC

    Anti-Human IgG4 pFc’ [HP6023] (FITC)

  • Alkaline Phosphatase

    Anti-Human IgG4 pFc’ [HP6023] (Alkaline Phosphatase)

  • Biotin

    Anti-Human IgG4 pFc’ [HP6023] (Biotin)

Key facts

Host species

Mouse

Target species

Human

Target isotype

IgG4

Target specificity

Fc region

Minimal cross-reactivity
Pre-adsorbed

No

Conjugation

PE

Excitation/Emission

Ex: 480;565nm, Em: 578nm

Applications

ELISA, IHC-Fr, ICC/IF, Dot, WB

applications

Clonality

Monoclonal

Clone number

HP6023

Isotype

IgG3

Light chain type

kappa

Immunogen

Full Length Protein corresponding to Human IGHG4. The exact immunogen used to generate this antibody is proprietary information.

P01861

Specificity

ab99819 reacts with the pFc’ portion of the heavy chain of IgG4.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Dot": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p>for Dot and slot immunoblotting</p>" }, "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "IHC-Fr": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "ICC/IF": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"0.1 µg for 10^6 Cells", "notes":"<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.3 Preservative: 0.093% Sodium azide Constituents: PBS, 1% Sucrose
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Store in the dark

Product protocols

Target data

Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound Igs serve as receptors, which upon binding to a specific antigen trigger the clonal expansion and differentiation of B lymphocytes into Ig-secreting plasma cells. Secreted Igs known as antibodies mediate the effector phase of humoral immunity by blocking the interaction of infectious antigens with cellular receptors (via the antigen-binding region) and eliciting effector mechanisms that lead to pathogen neutralization (via the constant region) (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The antigen-binding region is formed by the variable domain of one heavy chain paired with the variable domain of its associated light chain. Each Ig molecule has two antigen-binding sites with remarkable affinity for a particular antigen due to V-(D)-J rearrangement, somatic hypermutations and affinity maturation of the variable domains upon antigen exposure (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region defines the Ig isotype that perform distinct sets of effector functions. B cells diversify and rearrange their Ig constant regions through class-switch recombination, a process by which the constant region is switched from one Ig isotype to another, namely from IgM and IgD to IgG, IgA and IgE (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region interacts (via the fragment crystallizable, Fc) with the Fc receptors on innate immune cells to mediate humoral effector functions. Ig gamma-4 (IgG4) isotype does not elicit antibody-dependent cellular cytotoxicity (ADDC) or complement-dependent cytotoxicity (CDC). Instead it is likely involved in immune tolerance mechanisms to allergens and parasites either by blocking IgE-antigen complex formation or by directly inhibiting mast cell degranulation through Fc receptor signaling. In the context of tumorigenesis, it may participate in immunosuppressive mechanisms.
See full target information IGHG4

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Journal of neurology 271:2736-2744 PubMed38386048

2024

Different pain phenotypes are associated with anti-Caspr2 autoantibodies.

Applications

Unspecified application

Species

Unspecified reactive species

Patrik Greguletz,Maria Plötz,Carolin Baade-Büttner,Christian G Bien,Katharina Eisenhut,Christian Geis,Robert Handreka,Jaqueline Klausewitz,Peter Körtvelyessy,Stjepana Kovac,Andrea Kraft,Jan Lewerenz,Michael Malter,Michael Nagel,Felix von Podewils,Harald Prüß,Anna Rada,Johanna Rau,Sebastian Rauer,Rosa Rößling,Thomas Seifert-Held,Kai Siebenbrodt,Kurt-Wolfram Sühs,Simone C Tauber,Franziska Thaler,Judith Wagner,Jonathan Wickel,Frank Leypoldt,Heike L Rittner,Claudia Sommer,Carmen Villmann,Kathrin Doppler
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com